Exploring Innovations in Muscle Wasting Disease Treatment

January 23, 2025 / The Clinical Trial Vanguard Executive Interviews In this interview, we engage with David Craig from Sarcomatrix Therapeutics to discuss the development of S-969, a novel oral small molecule targeting the Hippo-YAP pathway. Our conversation covers regulatory challenges, clinical trial design, manufacturing scale-up, intellectual property protection, and strategic partnerships, offering insights into […]

Sarcomatrix Therapeutics and Celito Tech Announce Strategic Collaboration to Advance S-969 to the Clinic

RENO, NV, UNITED STATES, January 07, 2025 – Sarcomatrix Therapeutics, a biotech innovator in muscle disease therapies, today announced a strategic collaboration with Celito Tech to leverage cutting-edge technology solutions for advancing Sarcomatrix’s lead oral drug candidate, S-969, into clinical trials. This partnership will harness the power of the CELITO’s Helyx Platform and expertise to […]

Sarcomatrix to Present at Three Major Events During JPM Week 2025 in San Francisco

RENO, NV, UNITED STATES, January 6, 2025 /EINPresswire.com/ — Reno, NV – January 6, 2025 – Sarcomatrix Therapeutics, a pioneering biotech company advancing innovative therapies for muscle diseases, is proud to announce its participation in three high-profile events during the upcoming JPM Week 2025 in San Francisco. These presentations highlight Sarcomatrix’s continued commitment to scientific excellence […]

Sarcomatrix Therapeutics Strengthens Leadership Team with Appointment of Al Swarts as Chief of Technical Operations

RENO, NV, UNITED STATES, January 2, 2025 /EINPresswire.com/ — Sarcomatrix Therapeutics Strengthens Leadership Team with Appointment of Al Swarts as Chief of Technical Operations Sarcomatrix Therapeutics, a biotechnology company focused on developing innovative treatments for muscle diseases, is pleased to announce the addition of Al Swarts as Chief of Technical Operations. This strategic hire underscores […]

Sarcomatrix Therapeutics Corp.’s exclusive research Partner Strykagen Awarded SBIR Phase 2 Grant from the National Institutes of Health (NIH) to advance small molecules promoting muscle regeneration.

Sarcomatrix acquired rhLaminin-111 as a potential treatment for LAMA2-Related Dystrophies, a rare, life-threatening disease that causes respiratory insufficiency, poor muscle tone, muscle atrophy, scoliosis, and joint problems as well as delayed development of motor skills in children, from Prothelia, Inc.